Pancreatic Adenocarcinoma Treatment Market Size & Share, by Type (Chemotherapy, Targeted Therapy); Affected Area (Exocrine, Endocrine) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3373
  • Published Date: Apr 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Pancreatic Adenocarcinoma Treatment Landscape

    • Amgen Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffman-La Roche AG
    • Novartis AG
    • Pfizer Inc.
    • Aduro Biotech Inc.
    • Clovis Oncology Inc.
    • Threshold Pharmaceuticals Inc.
    • NewLink Genetics Corp
    • Infinity Pharmaceuticals Inc.
    • Celgene Corporation

Browse Key Market Insights with Data Illustration:


In The News

  • Amgen Inc.’s new drug targeting KRAS mutations was approved by the U.S. Food and Drug Administration. This is the first-ever therapy developed to treat KRAS cancers, which are often altered in the colon, lung, and pancreatic areas.

  • Novartis AG declared that US Food and Drug Administration granted the NIS793 with Orphan Drug Designation (ODD) along with standard chemotherapy care for the treatment of pancreatic cancer.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3373
  • Published Date: Apr 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the market growth are the increasing geriatric population around the world and the rising prevalence of obesity.

The market size of pancreatic adenocarcinoma treatment is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023-2035.

Lack of skilled professionals and side effects of chemo and radiotherapy are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., Threshold Pharmaceuticals Inc., NewLink Genetics Corp, Infinity Pharmaceuticals Inc., Celgene Corporation.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, affected area, and by region.

The exocrine segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying